COMP <GO>
BIIB vs UNH // REVENUE GROWTH (YOY)
Biogen Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BIIB 5
— UNH 8
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $249.01 (-1.82%) • MKT CAP: $36.81B
revenue-growth
2.20%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 88.31% | -12.61 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | 12.38% | -5.98 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.3x | 15.3x | +7.03 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | 6.25% | -0.69 | UNH | /fcf-yield <GO> |
| Operating Margin | 15.90% | 5.32% | +10.58 | BIIB | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 3.53% | +9.57 | BIIB | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 2.20% | 3.33% | -1.13 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 3.09 | +0.61 | BIIB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 55.1 | +3.90 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.33 | +0.77 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 17.7x | +8.76 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.81B | $359.43B | -$322.62B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | UNH REV | BIIB GROSS % | UNH GROSS % | BIIB FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $447.57B | 75.7% | 88.7% | $2.05B | $16.07B |
| FY 2024 | $9.68B | $400.28B | 76.1% | 88.3% | $2.72B | $20.70B |
| FY 2023 | $9.84B | $371.62B | — | 89.6% | $1.10B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
UNH // BETA 0.33